Publications by authors named "S Alfayate-Miguelez"
Article Synopsis
- This study evaluates nirsevimab, a monoclonal antibody, for preventing respiratory syncytial virus (RSV) infections in infants under ten months in Spain.
- It involved a large immunization campaign where infants born after April 1, 2023, received nirsevimab either at birth or through a catch-up program.
- Results showed nirsevimab had an overall effectiveness of 75.8% and 80.2% in the catch-up group, highlighting its role in reducing RSV-related illnesses in primary care settings.
A multifaceted, participatory, open program based on a qualitative and quantitative approach was developed in the Region of Murcia (Spain) aimed to reduce antibiotic use in children under 3 years of age diagnosed with upper respiratory tract infections (acute otitis media, pharyngitis, and common cold). Antibiotic consumption was measured using the defined daily dose per 1000 inhabitants per day (DHD). Pre-intervention data showed a prevalence of antibiotic prescriptions in the primary care setting of 45.
View Article and Find Full Text PDFEarly estimates of nirsevimab immunoprophylaxis effectiveness against hospital admission for respiratory syncytial virus lower respiratory tract infections in infants, Spain, October 2023 to January 2024.
Euro Surveill
February 2024
Article Synopsis
- * This effectiveness was validated through two different research methods (screening and test-negative) in a multicenter study across nine hospitals in three regions.
- * The antibody did not provide any protection against hospitalizations for lower respiratory tract infections caused by viruses other than RSV, and these findings could help influence public health policies.
Rotavirus (RV) is the most common cause of severe gastroenteritis (GE) in infants and young children worldwide and is associated with a significant clinical and economic burden. The objective of this study was to analyze the characteristics, healthcare resource utilization and the direct medical costs related to RVGE hospitalizations in Spain. An observational, multicenter, cross-sectional study was conducted from June 2013 to May 2018 at the pediatric departments of 12 hospitals from different Spanish regions.
View Article and Find Full Text PDFBackground: Rotavirus (RV) vaccines are available in Spain since 2006 but are not included in the National Immunization Program. RV vaccination has reached an intermediate vaccination coverage rate (VCR) but with substantial differences between provinces. The aim of this study was to assess the ratio of RV gastroenteritis (RVGE) admissions to all-cause hospitalizations in children under 5 years of age in areas with different VCR.
View Article and Find Full Text PDF